Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194400 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Resolve Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02194400 is a Phase 1 study that has completed, run by Resolve Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT02194400, a Phase 1 study, has completed, sponsored by Resolve Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
Interventions
- BIOLOGICAL RSLV-132
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02194400
The ClinicalTrials.gov registry entry for NCT02194400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resolve Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RSLV-132 is the first listed.
NCT02194400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02194400 about?
NCT02194400 is a clinical study titled "Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus". A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
What is the current status of trial NCT02194400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02194400?
The interventions under investigation include: RSLV-132 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02194400?
This trial is sponsored by Resolve Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.